Related Experiment Videos
[Adjuvant chemotherapy for breast cancer]
Gan No Rinsho. Japan Journal of Cancer Clinics
|August 1, 1983
Summary
Accurate axillary staging and estrogen receptor status predict occult breast cancer micrometastasis risk. Adjuvant chemotherapy and chemohormonal therapy are recommended for high-risk patients, with careful consideration of potential secondary neoplasm risks.
Area of Science:
- Oncology
- Breast Cancer Research
- Clinical Pathology
Context:
- Accurate staging is crucial for determining breast cancer recurrence risk.
- Estrogen receptor (ER) status influences treatment strategies for primary breast tumors.
- The potential for occult micrometastasis necessitates robust predictive markers.
Purpose:
- To identify key predictors of occult micrometastasis in breast cancer.
- To guide the selection of appropriate adjuvant therapies for high-risk patients.
- To evaluate the role of chemohormonal therapy in adjuvant breast cancer treatment.
Summary:
- Axillary staging and primary tumor estrogen receptor (ER) status are significant predictors of occult micrometastasis.
- Adjuvant chemotherapy is recommended for patients with a high risk of recurrence.
- Chemohormonal therapy, particularly for ER-positive (ER+) breast cancer, is an effective adjuvant measure.
- While the risk of secondary neoplasms from adjuvant chemotherapy requires further investigation, it cannot be disregarded.
Impact:
- Improved patient stratification for adjuvant therapy decisions.
- Enhanced selection of chemotherapeutic agents effective against both primary and recurrent disease.
- Informed clinical practice regarding the benefits and risks of adjuvant chemohormonal therapy in breast cancer.